a green heart beat on a black background

Healthcare and Life Sciences

Strategy, commercialization, and value creation under reimbursement pressure.

From Pipeline Choices to Board Decisions

CMI advises clinical-stage biopharma companies at board-level inflection points, typically within 6 to 18 months of first launch or a major capital event. When fundraising is constrained, and multiple scientific paths look viable, we help management teams and boards prioritize, allocate capital, and align technical and commercial milestones to valuation.

Our teams combine PhD-level scientific depth with strategy and financial modeling to produce decisions that withstand investor diligence, reimbursement scrutiny, and board debate.

Corporate Development, Engineered for Clinical Inflection Points

We translate complex science into a board executable plan. Milestones, capital path, and partnering strategy built to withstand diligence.

A group of people working on computers in a room

woman in white shirt standing in front of computer

Asset Value Optimization

Non-Diluitive Strategic Sponsors

Investor and Board Readiness

Indication and pipeline prioritization, kill criteria, and resource reallocation.
Technical plan mapped to valuation inflection points, endpoints, timing, and budget.
Scenario model tied to cash runway and dilution math.

Non-dilutive funding strategy, SBIR, STTR, foundation, and disease advocacy pathways.
Partnering strategy, licensing, co-development, or regional rights.
Value story and diligence package that survives investor scrutiny.

Diligence grade data room, IP narrative, clinical evidence package, and risk register.
Board materials that force clear choices, investment cases, and downside scenarios.
Financing strategy, terms sensitivity, and milestone-based use of proceeds.